●March-Listed at Hongkong Stock Exchange main board.Stock code:06833-HK.

●September Shanghai company and operations center was established

●November acquisition 100% stake of Qingdao Ruichi Pharmaceutical Co., Ltd.

●  January - Hong Kong Prosperous established cooperation with Trendful, the exclusive sales agent for Bruschettini and Foscama, through a distribution authorization agreement with Vast Surplus.

●  September - We have entered into a collaboration agreement with Liaoning Wanjia to become the exclusive service provider for Xinneng Q10, a dietary supplement registered with the CFDA, in China. 

●  February - Chengdu Sinco Pharmaceuticals, located in Sichuan Shuangliu Bonded Area, was established by Sinco Biotechnology, with a primary focus on the design, operation and management of a cold chain facility and aims to be one of the largest cold chain centers in Southwest China.

●  November - Sichuan Sinco Biotechnology Co., Ltd. was established with primary focus on research and development.

●  November - We established a long-term partnership with Octapharma through signing a long-term distribution agreement, pursuant to which we became a MPCMS provider in China for Octapharma in 24 provinces and regions. In August 2015, Octapharma confirmed our exclusive right to service Human Albumin Solution in these provinces and regions.

● April - Sichuan Sinco Pharmaceuticals was established.

● April - We established a long-term partnership with Medochemie through signing an exclusive distribution agreement with Medochemie’s agent, pursuant to which we became the exclusive MPCMS provider in China for Axetine and Medocef manufactured by Medochemie.

● November - We entered into the first sales contract with Suzhou Zhongxin Pharmaceuticals Company Limited for the distribution of Axetine and Medocef, and formulated the marketing and promotional strategies to facilitate the sales.